

Press Release

Joachim Weith
Senior Vice President
Corporate Communications &
Governmental Affairs

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2101
F +49 6172 608-2294
joachim.weith@fresenius.com
www.fresenius.com

October 23, 2014

Fresenius nominates Allianz CEO Michael Diekmann for Supervisory Board

The Supervisory Board of Fresenius SE & Co. KGaA will propose that the next Annual General Meeting elect Mr. Michael Diekmann to the Supervisory Board. The Supervisory Board believes that his immense expertise and experience qualify Mr. Diekmann for the position of Deputy Chairman, which is now vacant. If elected to the Board, Mr. Diekmann has declared that he will seek this post.

Mr. Michael Diekmann, 59, has served as Chief Executive Officer of Allianz SE since April 2003. He has been member of the company's Management Board since 1998. He is currently a member of the Supervisory Boards of Siemens AG, BASF SE and Linde AG, serving as Deputy Chairman at the latter two companies. After reaching the age limit for Management Board members at Allianz SE, Mr. Diekmann will retire as member of the Management Board in May 2015.

Fresenius SE & Co. KGaA is required to appoint a new Supervisory Board member following the death of Dr. Gerhard Rupprecht, who served as the Board's Deputy Chairman.

#

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2013, Group sales were €20.3 billion. On June 30, 2014, the Fresenius Group had 209,933 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Dr. Ulf M. Schneider (Chairman), Dr. Francesco De Meo, Dr. Jürgen Götz,

Mats Henriksson, Rice Powell, Stephan Sturm, Dr. Ernst Wastler

Chairman of the Supervisory Board: Dr. Gerd Krick